Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,600.84
(
0.68%
)
US TECH 100
23,543.08
(
0.79%
)
Dow Jones
46,466.84
(
0.74%
)
Brent Oil
97.67
(
1.21%
)
Bitcoin
71,227.44
(
1.01%
)
News Focus
News Focus
Post# of 257285
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 223210

Tuesday, 02/26/2019 4:29:08 PM

Tuesday, February 26, 2019 4:29:08 PM

Post# of 257285
RVNC 4Q18 results—2019 cash-burn guidance=$148-158M*:

https://investors.revance.com/news-releases/news-release-details/revance-releases-fourth-quarter-and-full-year-2018-results

The FDA agreed that the 351(k) pathway is appropriate for the Botox-biosimilar program partnered with MYL.

Guidance for the RT002 BLA submission remains “1H19”.

*RVNC’s 1/31/19 cash was $296M, according to the CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today